Abbott tops consensus expectations regardless of decline in COVID-19 testing associated gross sales By Investing.com
© Reuters. Abbott (ABT) tops consensus expectations regardless of decline in Covid-19 testing associated gross sales
By Sam Boughedda
Abbott (NYSE:) shares fell Wednesday regardless of topping consensus expectations for revenue and income.
The medical system agency reported adjusted fourth-quarter of $1.03 per share, $0.11 higher than the analyst estimate of $0.92.
Income for the quarter got here in at $10.1 billion versus the consensus estimate of $9.62B. Regardless of topping consensus estimates, the corporate stated income fell 12% year-over-year, negatively impacted by an anticipated decline in COVID-19 testing-related gross sales.
“We considerably exceeded the EPS steerage we supplied at first of final 12 months regardless of difficult world enterprise situations,” stated Robert Ford, chairman and chief government officer of Abbott. “Our R&D pipeline continues to be extremely productive with a number of current and upcoming new product launches that place us properly going ahead.”
Trying ahead, Abbott sees FY2023 EPS between $4.30 and $4.50, consistent with the consensus estimate of $4.40.
Following the earnings launch, Stifel analysts stated there have been few surprises.
“Abbott’s Covid testing enterprise as soon as once more helped ship above-Consensus prime and bottom-line efficiency, with 4Q22 gross sales at $10.1B beating Stifel/Consensus $9.45B/$9.6B projections,” they stated. “EPS at $1.03 was additionally forward of Stifel/Consensus $0.88/$0.92. Our 4Q22 estimates integrated $500M Covid take a look at gross sales, whereas the corporate bought $1.069B…successfully all the distinction between our projections and Abbott top-line outcomes.”
